Core Viewpoint - Milestone Scientific Inc. is experiencing increased adoption of its CompuFlo® Epidural System, driven by favorable Medicare payment rates and a focus on expanding its presence in federal healthcare settings [2][3]. Business Update - The company reported a slight revenue decrease to approximately $2.2 million for the first quarter ended March 31, 2025, compared to the same period in 2024 [3]. - Medical revenue saw a significant increase to approximately $51,000 in Q1 2025 from $7,400 in Q1 2024, indicating growing traction for the CompuFlo technology [3]. - The company is actively engaging with Jurisdictional Medicare Administrative Contractors (JMACs) to expand its reimbursement framework, which is seen as a critical catalyst for adoption [2]. Financial Performance - Gross profit for Q1 2025 was $1.6 million, representing 74% of revenue, slightly down from 75% in Q1 2024 [4]. - The operating loss increased to approximately $(2.0) million in Q1 2025 from $(1.5) million in Q1 2024 [4]. - The net loss for Q1 2025 was approximately $(2.0) million, or $(0.02) per share, compared to a net loss of $(1.4) million, or $(0.02) per share, in Q1 2024 [5]. Strategic Initiatives - The company has secured a contract under the Federal Supply Schedule (FSS) to facilitate access to CompuFlo in federal healthcare settings, including the Department of Veterans Affairs and the Department of Defense [2]. - Milestone Scientific has maintained stable performance in its dental business while exercising financial discipline, including delaying non-essential R&D [2]. - The company secured $800,000 in convertible financing from board members, indicating strong confidence in its growth trajectory [2].

Core Insights - Milestone Scientific Inc. is focusing on expanding its CompuFlo® Epidural System in the U.S. following favorable Medicare pricing assignments, which significantly broaden the addressable market for the technology [3][4] - The company reported a decrease in total revenue for 2024, amounting to approximately $8.6 million, down from $9.8 million in 2023, while e-commerce revenue showed growth [4][6] - The company is optimistic about its future growth prospects in both the dental and medical segments, with positive initial performance in Q1 2025 [3][7] Business Update - The company has established reimbursement infrastructure for the CompuFlo® Epidural System, with Medicare Part B payment rates assigned in multiple states, enhancing market access [3] - A contract for the Federal Supply Schedule (FSS) has been awarded, allowing federal medical facilities to purchase the CompuFlo system, targeting adoption within the U.S. Department of Veterans Affairs and other federal healthcare systems [3] - Strong commercial traction is noted in the private sector, with new rollouts at various pain management clinics and ambulatory surgery centers [3] Financial Performance - Revenue for 2024 was approximately $8.6 million, a decrease of about $1.2 million from 2023 [4] - E-commerce revenue reached approximately $5.1 million in 2024, compared to $4.8 million in 2023, indicating growth in this segment [4] - The company recorded an operating loss of $6.8 million in 2024, an improvement from a loss of $7.1 million in 2023, driven by higher-margin e-commerce sales [7] Market Position - The STA Single Tooth Anesthesia System remains a leader in computer-controlled local anesthetic delivery, with over 95 million injections administered to date [3] - The company is leveraging its leadership in the dental segment through an expanded direct-to-consumer e-commerce platform, which is enhancing margins and customer engagement [3] - The clinical response to the CompuFlo system has been positive, positioning the company to capitalize on growth opportunities in the medical field [3][7]

Core Insights - Milestone Scientific Inc. is expanding the adoption of its CompuFlo® Epidural System in pain management clinics and ambulatory surgery centers following favorable Medicare pricing assignments in multiple U.S. states [1][2] - The company reported a decrease in total revenue for 2024, amounting to approximately $8.6 million, down from $9.8 million in 2023, while e-commerce revenue showed growth [3][4] - The company is optimistic about its future growth prospects in both the dental and medical segments, with positive initial performance in Q1 2025 [2][6] Business Update - The company has established a reimbursement infrastructure for the CompuFlo® Epidural System, with favorable Medicare Part B payment rates assigned by First Coast Service Options and Novitas Solutions [2] - The Medicare pricing decisions have expanded the addressable market significantly, and the company is pursuing further reimbursement approvals to enhance national expansion [2] - A contract for the Federal Supply Schedule has been awarded, allowing federal medical facilities to purchase the CompuFlo system, targeting adoption within the U.S. Department of Veterans Affairs and other federal healthcare systems [2] Financial Performance - Total revenue for 2024 was approximately $8.6 million, a decrease of about $1.2 million from 2023 [3] - E-commerce revenue reached approximately $5.1 million in 2024, compared to $4.8 million in 2023, indicating growth in this segment [3] - The company recorded an operating loss of $6.8 million in 2024, an improvement from a loss of $7.1 million in 2023, driven by higher-margin e-commerce sales [6] Market Position - The STA Single Tooth Anesthesia System remains a leader in computer-controlled local anesthetic delivery, with over 95 million injections administered to date [2] - The company is seeing strong commercial traction in the private sector, with new rollouts at various pain management clinics and ambulatory surgery centers [2] - The strategic partnership with Axial Biologics is enhancing the distribution footprint in key U.S. markets [2]